This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Castle, P. E. Articles by Lorincz, A. Search for Related Content PubMed PubMed Citation Articles by Castle, P. E. Articles by Lorincz, A.

Restricted Cross-Reactivity of Hybrid Capture 2 with Nononcogenic Human Papillomavirus Types¹

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892 [P. E. C., M. S., S. W., A. H., M. E. S.]; Albert Einstein College of Medicine, Bronx, New York 10461 [R. D. B.]; Proyecto Epidemiologico Guanacaste, San Jose, Costa Rica [R. H., M. C. B.]; and Digene Corporation, Gaithersburg, Maryland 20878 [A. L.]

Hybrid Capture 2 Test using probe B (HC2-B) is a clinical test for the detection of 13 human papillomavirus (HPV) types associated with cervical cancer (oncogenic types), but the potential clinical significance of HC2-B cross-reactivity with untargeted (nononcogenic) HPV types has not been fully evaluated. Thus, HC2-B test results on 954 clinical cervical specimens from a population-based natural history study of HPV in Costa Rica were compared with the data from testing of the same specimens twice by HPV type-specific MY09/MY11 L1 consensus primer PCR. Specimens positive by PCR for single HPV types not targeted by HC2-B were used for determining type-specific cross-reactivity. Effects of cross-reactivity on clinical performance were estimated by calculating sensitivity and specificity with and without cross-reactivity for the detection of high-grade cervical lesions. HC2-B tested positive for single infections by untargeted (cross-reactive) types 11, 53, 61, 66, 67, 70, 71, and 81. Cross-reactivity was strongly associated with PCR signal strength (P_Trend = 0.0001) and cervical abnormalities (P = 0.0002, Pearson ²). We estimated that HC2-B cross-reactivity resulted in minor changes in screening performance. Clinical sensitivity increased from 84.3% to 87.9%, clinical specificity decreased from 89.6% to 88.1%, and referral rates increased from 11.7% to 13.2% for detection of cervical intraepithelial neoplasia grade 2. The clinical effect of cross-reactivity varied by cytologic interpretation. Among women with normal cytologic interpretations, cross-reactivity significantly improved the accuracy of identifying cytologically nonevident histology of cervical intraepithelial neoplasia grade 2 because of increased sensitivity with maintained specificity. However, among women with equivocal or mildly abnormal cytologic interpretations, cross-reactivity decreased the accuracy of HPV testing because of substantial decreases in specificity. In summary, cross-reactivity with nononcogenic HPV types had little effect on the overall clinical performance of HC2-B as a general screening test, but reduction of cross-reactivity might improve the performance of HPV testing for triage of equivocal or mildly abnormal cytologic interpretations.

This article has been cited by other articles:

				P. E. Gravitt, M. Schiffman, D. Solomon, C. M. Wheeler, and P. E. Castle A Comparison of Linear Array and Hybrid Capture 2 for Detection of Carcinogenic Human Papillomavirus and Cervical Precancer in ASCUS-LSIL Triage Study Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1248 - 1254. [Abstract] [Full Text] [PDF]

				P. E. Castle, J. T. Cox, J. Jeronimo, D. Solomon, C. M. Wheeler, P. E. Gravitt, and M. Schiffman An Analysis of High-Risk Human Papillomavirus DNA-Negative Cervical Precancers in the ASCUS-LSIL Triage Study (ALTS) Obstet. Gynecol., April 1, 2008; 111(4): 847 - 856. [Abstract] [Full Text] [PDF]

				G. F. Sawaya Adding Human Papillomavirus Testing to Cytology for Primary Cervical Cancer Screening: Shooting First and Asking Questions Later Ann Intern Med, April 1, 2008; 148(7): 557 - 559. [Full Text] [PDF]

				P. E. Castle, P. E. Gravitt, D. Solomon, C. M. Wheeler, and M. Schiffman Comparison of Linear Array and Line Blot Assay for Detection of Human Papillomavirus and Diagnosis of Cervical Precancer and Cancer in the Atypical Squamous Cell of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion Triage Study J. Clin. Microbiol., January 1, 2008; 46(1): 109 - 117. [Abstract] [Full Text] [PDF]

				M. P. Stevens, S. M. Garland, E. Rudland, J. Tan, M. A. Quinn, and S. N. Tabrizi Comparison of the Digene Hybrid Capture 2 Assay and Roche AMPLICOR and LINEAR ARRAY Human Papillomavirus (HPV) Tests in Detecting High-Risk HPV Genotypes in Specimens from Women with Previous Abnormal Pap Smear Results J. Clin. Microbiol., July 1, 2007; 45(7): 2130 - 2137. [Abstract] [Full Text] [PDF]

				M. Safaeian, R. Herrero, A. Hildesheim, W. Quint, E. Freer, L.-J. Van Doorn, C. Porras, S. Silva, P. Gonzalez, M. C. Bratti, et al. Comparison of the SPF10-LiPA System to the Hybrid Capture 2 Assay for Detection of Carcinogenic Human Papillomavirus Genotypes among 5,683 Young Women in Guanacaste, Costa Rica J. Clin. Microbiol., May 1, 2007; 45(5): 1447 - 1454. [Abstract] [Full Text] [PDF]

				P. E. Castle, J. Dockter, C. Giachetti, F. A.R. Garcia, M. K. McCormick, A. L. Mitchell, E. B. Holladay, and D. P. Kolk A Cross-sectional Study of a Prototype Carcinogenic Human Papillomavirus E6/E7 Messenger RNA Assay for Detection of Cervical Precancer and Cancer Clin. Cancer Res., May 1, 2007; 13(9): 2599 - 2605. [Abstract] [Full Text] [PDF]

				C. Payan, A. Ducancelle, M. H. Aboubaker, J. Caer, M. Tapia, A. Chauvin, D. Peyronnet, E. Le Hen, Z. Arab, M.-C. Legrand, et al. Human Papillomavirus Quantification in Urine and Cervical Samples by Using the Mx4000 and LightCycler General Real-Time PCR Systems J. Clin. Microbiol., March 1, 2007; 45(3): 897 - 901. [Abstract] [Full Text] [PDF]

				P. E. Castle, M. Sadorra, F. Garcia, E. B. Holladay, and J. Kornegay Pilot Study of a Commercialized Human Papillomavirus (HPV) Genotyping Assay: Comparison of HPV Risk Group to Cytology and Histology J. Clin. Microbiol., November 1, 2006; 44(11): 3915 - 3917. [Abstract] [Full Text] [PDF]

				A. T. Hesselink, N. W. J. Bulkmans, J. Berkhof, A. T. Lorincz, C. J. L. M. Meijer, and P. J. F. Snijders Cross-Sectional Comparison of an Automated Hybrid Capture 2 Assay and the Consensus GP5+/6+ PCR Method in a Population-Based Cervical Screening Program. J. Clin. Microbiol., October 1, 2006; 44(10): 3680 - 3685. [Abstract] [Full Text] [PDF]

				D. van Hamont, M. A. P. C. van Ham, J. M. J. E. Bakkers, L. F. A. G. Massuger, and W. J. G. Melchers Evaluation of the SPF10-INNO LiPA Human Papillomavirus (HPV) Genotyping Test and the Roche Linear Array HPV Genotyping Test. J. Clin. Microbiol., September 1, 2006; 44(9): 3122 - 3129. [Abstract] [Full Text] [PDF]

				T Karwalajtys, M Howard, J W Sellors, and J Kaczorowski Vaginal self sampling versus physician cervical sampling for HPV among younger and older women. Sex. Transm. Inf., August 1, 2006; 82(4): 337 - 339. [Abstract] [Full Text] [PDF]

				M. T. Sandri, P. Lentati, E. Benini, P. Dell'Orto, L. Zorzino, F. M. Carozzi, P. Maisonneuve, R. Passerini, M. Salvatici, C. Casadio, et al. Comparison of the Digene HC2 Assay and the Roche AMPLICOR Human Papillomavirus (HPV) Test for Detection of High-Risk HPV Genotypes in Cervical Samples. J. Clin. Microbiol., June 1, 2006; 44(6): 2141 - 2146. [Abstract] [Full Text] [PDF]

				P. E. Castle, J. Jeronimo, M. Schiffman, R. Herrero, A. C. Rodriguez, M. C. Bratti, A. Hildesheim, S. Wacholder, L. R. Long, L. Neve, et al. Age-Related Changes of the Cervix Influence Human Papillomavirus Type Distribution Cancer Res., January 15, 2006; 66(2): 1218 - 1224. [Abstract] [Full Text] [PDF]

				P. E. Castle, D. Solomon, M. Schiffman, C. M. Wheeler, and for the ALTS Group Human Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities J Natl Cancer Inst, July 20, 2005; 97(14): 1066 - 1071. [Abstract] [Full Text] [PDF]

				K. McIntyre-Seltman, P. E. Castle, R. Guido, M. Schiffman, C. M. Wheeler, and for The ALTS Group Smoking Is a Risk Factor for Cervical Intraepithelial Neoplasia Grade 3 among Oncogenic Human Papillomavirus DNA-Positive Women with Equivocal or Mildly Abnormal Cytology Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1165 - 1170. [Abstract] [Full Text] [PDF]

				S. S. Wang, M. Schiffman, and for The ALTS Group Medication Use, Medical Conditions, and the Risk of Human Papillomavirus Infection and Subsequent Cervical Intraepithelial Neoplasia 3 Among Women with Mild Cytologic Abnormalities Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 542 - 545. [Full Text] [PDF]

				M. E. Sherman, S. S. Wang, C. M. Wheeler, L. Rich, P. E. Gravitt, R. Tarone, and M. Schiffman Determinants of Human Papillomavirus Load among Women with Histological Cervical Intraepithelial Neoplasia 3: Dominant Impact of Surrounding Low-Grade Lesions Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 1038 - 1044. [Abstract] [Full Text] [PDF]

				P. E. Castle, A. T. Lorincz, D. R. Scott, M. E. Sherman, A. G. Glass, B. B. Rush, S. Wacholder, R. D. Burk, M. M. Manos, J. E. Schussler, et al. Comparison between Prototype Hybrid Capture 3 and Hybrid Capture 2 Human Papillomavirus DNA Assays for Detection of High-Grade Cervical Intraepithelial Neoplasia and Cancer J. Clin. Microbiol., September 1, 2003; 41(9): 4022 - 4030. [Abstract] [Full Text] [PDF]

				P. E. Gravitt, R. D. Burk, A. Lorincz, R. Herrero, A. Hildesheim, M. E. Sherman, M. C. Bratti, A. C. Rodriguez, K. J. Helzlsouer, and M. Schiffman A Comparison between Real-Time Polymerase Chain Reaction and Hybrid Capture 2 for Human Papillomavirus DNA Quantitation Cancer Epidemiol. Biomarkers Prev., June 1, 2003; 12(6): 477 - 484. [Abstract] [Full Text] [PDF]

				T. Iftner and L. L. Villa Chapter 12: Human Papillomavirus Technologies J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 80 - 88. [Abstract] [Full Text] [PDF]